Treatment Information


Lung Cancer treatment details. Biologic therapy.

Tohoku University, Sendai, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:3City/State/Province:Sendai
Treatments:Biologic therapyHospital:Tohoku University
Date:Jul 2006


Patients: This Phase II trial involved a total of 75 patients with advanced non-small-cell lung cancer. There were 30 men and 45 women. Subtypes included adenocarcinoma (64 patients) and non-adenocarcinoma (11 patients). None of the patients had previous chemotherapy.

Treatment: The treatment consisted of biological therapy – Iressa (Gefitinib) an oral tyrosine kinase inhibitor of the epidermal growth factor receptor.

Toxicity: Grade 3 toxicities included elevation of a hepatic enzyme.

Results: The median overall survival was not reported.

Correspondance: Akira Inoue, MD